神经粘附分子CHL1在神经系统中的研究进展

粘附分子通过介导细胞间相互作用发挥其在发育、再生和突触修饰等方面的重要作用.神经细胞粘附分子CHL1(close homologue of L1)是近年发现的粘附分子,属于粘附分子免疫球蛋白超家族,集中表达于神经系统,通过亲异性作用(heterophilic interaction)介导细胞与细胞、细胞与胞外基质的相互作用,进而参与神经系统的发育、轴突的生长、迁移及导向等过程.     

钙依粘附蛋白和神经细胞粘附分子的结构与功能

钙依粘附蛋白和神经细胞粘附分子的结构与功能关键词Ｃａｄｈｅｒｉｎ,Ｎ－ＣＡＭ细胞－细胞粘附分子有两类,一类是钙依粘附蛋白（Ｃａｄｈｅｒｉｎ）,一类是不依赖钙的细胞粘附分子。１．Ｃａｄｈｅｒｉｎ脊椎动物的Ｃａｄｈｅｒｉｎ按发现其存在其中的主要组织分为三...     

菌群失调症患者体内sICAM-1活性表达和血小板分布情况

探讨老年肠道功能性腹泻致菌群失调症时,患者血浆中可溶性细胞间粘附分子sICAM-1表达,以及外周血小板分布情况。我们检测了50例老年胃肠功能性腹泻所致菌群失调症患者的用药前与用药后的血浆可溶性细胞间粘附分子sICAM-1,凝血功能检测凝血酶原时间（PT）、活化部分凝血酶原时间（APTT）,并进行血浆纤维蛋白原测定,以及血小板光学散射分析,了解正常菌群分布对相关指标的影响。     

神经细胞粘附分子的研究进展

神经系统的正常发育依赖于细胞与局部环境间复杂的相互作用,这种相互作用受几种细胞粘附分子的介导,神经系统表达多种粘附分子,它们在神经管形成,神经元迁移,迁移后分化,以及成熟神经元结构维持中具有相当重要的作用。另外,细胞粘附分子还促进接触依赖性细胞间连接的形成。     

复方抗敏灵对哮喘大鼠ICAM—1表达及PLA2的影响

采用卵蛋白等致敏大鼠哮喘模型,观察正常组、哮喘组和中药治疗组大鼠支气管肺泡上皮细胞粘附分子（ICAM－1）的表达情况及支气管肺泡灌洗液（BALF）中磷脂酶A2（PLA2）活性变化,以及BALF中细胞总数及细胞分类情况。结果表明：复方抗敏灵能够抑制哮喘大鼠肺组织ICAM－1表达（P＜0.01）;显著降低哮喘大鼠BALF中PLA2活性（P＜0．01）;同时,具有降低哮喘大鼠BALF中各种炎性细胞的作用（P＜0．01）。     

细胞粘附分子研究现状

细胞粘附分子是指由细胞合成、存在于细胞膜或胞外、可促进细胞粘附的一大类分子的总称。研究表明,细胞粘附分子在胚胎发育、伤口愈合、学习与记忆的神经机制以及病毒感染、肿瘤转移等多种生理和病理过程中均发挥重要作用。研究细胞粘附分子既可以帮助我们了解机体的重要生理过程和病理机制,并为肿瘤、ＡＩＤＳ的治疗提供新的手段。细胞粘附分子（ｃｅｌｌａｄｈｅｓｉｏｎｍｏｌｅｃｕｌｅｓ,ＣＡＭ）是多细胞生物的重要功能分子,在形成组织器官的正常结构与功能、细胞的游走与运动、机体的发育与成长、伤口的愈合、神经的再生、病毒感染、肿瘤转移等方面均有重要作用。     

创伤后多脏器功能衰竭患者白细胞流变性 和细胞粘附分子水平的变化

目的：探讨创伤后多器官功能衰竭（MOF）患者白细胞流变性和细胞粘附分子（CAMs）水平的变化。方法：采用DXC-300A型核孔膜红细胞变形能力测定仪、JYJ-Ⅲ型体外血栓血小板粘附两用仪、酶联免疫吸附法（ELISA）,分别检测了36例创伤后MOF患者、31例创伤患者和35例健康人外周血液白细胞变形能力（LD）、白细胞粘附功能（LAF）、白细胞CD18表达、血浆可溶性细胞间粘附分子-1（sICAM-1）和可溶性血管细胞间粘附分子-1（sVCAM—1）的变化。结果：MOF患者白细胞滤过指数（LFI）、白细胞粘附率（LAR）、白细胞CD180表达、sICAM—1,sVCAM—1均明显增高,与对照组和创伤组比较差异有极显著性（F=68．45-116．20,q=12．161—21、374,P〈0．001）,MOF组死亡者各指标变化较存活者更明显（t=6．920—11．665,P〈0,001）。MOF患者LFI和LAR与sICAM—1,sVCAM—1和白细胞CD18表达呈正相关（r=0．691～0．844,P〈0．001）,LFI与LAR呈正相关（r=0．771,P〈0．001）。结论：白细胞流变性和CAMs水平异常参与了MOF的发生,且与病情严重程度有密切关系。     

血液疾患与细胞粘附分子

血液疾患与细胞粘附分子阎有功,马丽瑛（广州军区武汉总医院检验科,武汉）（卫生部武汉卫生检疫局,武汉４３００６０）关键词细胞粘附分子,造血,血液疾患多细胞生物存在精细的细胞间网状结构,它与细胞相互接触、传递细胞内信息有关,这些结构称为细胞粘附分子（ＣＡ...     

内皮细胞粘附分子与血管壁通透性

内皮细胞是血管壁的主要通透屏障,对血管壁通透性有多种调节作用。细胞粘附分参与细胞间连接形成以及细胞－基底膜间的粘附,与内皮层连续完整性以及通透性密切相关。参与内皮细胞中间连接的粘附分子有三大家庭,即整合素家庭、钙依赖性粘附素家族和免疫球蛋白家族,对这些粘附分子家族的研究有助于阐明内皮细胞损伤修复、新生血管形成、血管通透性调节以及循环血细胞游出的机制。     

P－选择素研究进展

Ｐ－选择素是粘附分子选择素家族的重要成分之一,参与细胞间、细胞与基质间的粘附,在炎症、栓塞及肿瘤转移中起重要作用．本文着重介绍了Ｐ－选择素的结构特点、配体、表达调控及检测方面的研究进展．     

Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells

Intercellular adhesion molecule-1 (ICAM-1) on the surface of cultured umbilical vein and saphenous vein endothelial cells was upregulated between 2.5- and 40-fold by rIL-1, rTNF, LPS and rIFN gamma corresponding to up to 5 X 10(6) sites/cell. Endothelial cell ICAM-1 was a single band of 90 kD in SDS-PAGE. Purified endothelial cell ICAM-1 reconstituted into liposomes and bound to plastic was an excellent substrate for both JY B lymphoblastoid cell and T lymphoblast adhesion. Adhesion to endothelial cell ICAM-1 in planar membranes was blocked completely by monoclonal antibodies to lymphocyte function associated antigen-1 (LFA-1) or ICAM-1. Adhesion to artificial membranes was most sensitive to ICAM-1 density within the physiological range found on resting and stimulated endothelial cells. Adhesion of JY B lymphoblastoid cells, normal and genetically LFA-1 deficient T lymphoblasts and resting peripheral blood lymphocytes to endothelial cell monolayers was also assayed. In summary, LFA-1 dependent (60-90% of total adhesion) and LFA-1-independent basal adhesion was observed and the use of both adhesion pathways by different interacting cell pairs was increased by monokine or lipopolysaccharide stimulation of endothelial cells. The LFA-1-dependent adhesion could be further subdivided into an LFA-1/ICAM-1-dependent component which was increased by cytokines and a basal LFA-1-dependent, ICAM-1-independent component which did not appear to be affected by cytokines. We conclude that ICAM-1 is a regulated ligand for lymphocyte-endothelial cell adhesion, but at least two other major adhesion pathways exist.     

A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1

Homotypic adhesion by phorbol ester-stimulated lymphocytes requires LFA-1 and Mg+2 and does not involve like-like interactions between LFA-1 molecules on adjacent cells. The latter finding suggested that a second molecule, distinct from LFA-1, also participates in LFA-1-dependent adhesion. The identification of such a molecule was the object of this investigation. After immunization with LFA-1-deficient EBV-transformed lymphoblastoid cells, a MAb was obtained that inhibits phorbol ester-stimulated aggregation of LFA-1+ EBV lines. This MAb defines a novel cell surface molecule, which is designated intercellular adhesion molecule 1 (ICAM-1). ICAM-1 is distinct from LFA-1 in both cell distribution and structure. In SDS-PAGE, ICAM-1 isolated from JY cells is a single chain of Mr = 90,000. As shown by MAb inhibition, ICAM-1 participates in phorbol ester-stimulated adhesion reactions of B lymphocyte and myeloid cell lines and T lymphocyte blasts. However, aggregation of one T lymphocyte cell line (SKW-3) was inhibited by LFA-1 but not ICAM-1 MAb. It is proposed that ICAM-1 may be a ligand in many, but not all, LFA-1-dependent adhesion reactions.     

Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1)

Lymphocyte function-associated antigen 1 (LFA-1) is a leukocyte cell surface glycoprotein that promotes intercellular adhesion in immunological and inflammatory reactions. It is an alpha beta complex that is structurally related to receptors for extracellular matrix components, and thus belongs to the integrin family. ICAM-1 (intercellular adhesion molecule-1) is a distinct cell surface glycoprotein. Its broad distribution, regulated expression in inflammation, and involvement in LFA-1-dependent cell-cell adhesion have suggested that ICAM-1 may be a ligand for LFA-1. We have purified ICAM-1 and incorporated it into artificial supported lipid membranes. LFA-1+ but not LFA-1- cells bound to ICAM-1 in the artificial membranes, and the binding could be specifically inhibited by anti-ICAM-1 treatment of the membranes or by anti-LFA-1 treatment of the cells. The cell binding to ICAM-1 required metabolic energy production, an intact cytoskeleton, and the presence of Mg2+ and was temperature dependent, characteristics of LFA-1- and ICAM-1-dependent cell-cell adhesion.     

ICAM-3 interacts with LFA-1 and regulates the LFA-1/ICAM-1 cell adhesion pathway

The interaction of lymphocyte function-associated antigen-1 (LFA-1) with its ligands mediates multiple cell adhesion processes of capital importance during immune responses. We have obtained three anti-ICAM-3 mAbs which recognize two different epitopes (A and B) on the intercellular adhesion molecule-3 (ICAM-3) as demonstrated by sequential immunoprecipitation and cross-competitive mAb-binding experiments. Immunoaffinity purified ICAM-3-coated surfaces were able to support T lymphoblast attachment upon cell stimulation with both phorbol esters and cross-linked CD3, as well as by mAb engagement of the LFA-1 molecule with the activating anti-LFA-1 NKI-L16 mAb. T cell adhesion to purified ICAM-3 was completely inhibited by cell pretreatment with mAbs to the LFA-1 alpha (CD11a) or the LFA-beta (CD18) integrin chains. Anti-ICAM-3 mAbs specific for epitope A, but not those specific for epitope B, were able to trigger T lymphoblast homotypic aggregation. ICAM-3-mediated cell aggregation was dependent on the LFA-1/ICAM-1 pathway as demonstrated by blocking experiments with mAbs specific for the LFA-1 and ICAM-1 molecules. Furthermore, immunofluorescence studies on ICAM-3-induced cell aggregates revealed that both LFA-1 and ICAM-1 were mainly located at intercellular boundaries. ICAM-3 was located at cellular uropods, which in small aggregates appeared to be implicated in cell-cell contacts, whereas in large aggregates it appeared to be excluded from cell-cell contact areas. Experiments of T cell adhesion to a chimeric ICAM-1-Fc molecule revealed that the proaggregatory anti-ICAM-3 HP2/19 mAb was able to increase T lymphoblast attachment to ICAM-1, suggesting that T cell aggregation induced by this mAb could be mediated by increasing the avidity of LFA-1 for ICAM-1. Moreover, the HP2/19 mAb was costimulatory with anti-CD3 mAb for T lymphocyte proliferation, indicating that enhancement of T cell activation could be involved in ICAM-3-mediated adhesive phenomena. Altogether, our results indicate that ICAM-3 has a regulatory role on the LFA-1/ICAM-1 pathway of intercellular adhesion.     

Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1)

ICAM-1 is a cell surface glycoprotein originally defined by a monoclonal antibody (MAb) that inhibits phorbol ester-stimulated leukocyte aggregation. Staining of frozen sections and immunofluorescence flow cytometry showed intercellular adhesion molecule-1 (ICAM-1) is expressed on non-hematopoietic cells such as vascular endothelial cells, thymic epithelial cells, certain other epithelial cells, and fibroblasts, and on hematopoietic cells such as tissue macrophages, mitogen-stimulated T lymphocyte blasts, and germinal center dendritic cells in tonsils, lymph nodes, and Peyer's patches. ICAM-1 staining on vascular endothelial cells is most intense in T cell areas in lymph nodes and tonsils showing reactive hyperplasia. ICAM-1 is expressed in low amounts on peripheral blood leukocytes. Phorbol ester-stimulated differentiation of myelomonocytic cell lines greatly increases ICAM-1 expression. ICAM-1 expression on dermal fibroblasts is increased threefold to fivefold by either interleukin 1 (IL 1) or interferon-gamma at 10 U/ml over a period of 4 or 10 hr, respectively. The induction is dependent on protein and mRNA synthesis and is reversible. ICAM-1 displays Mr heterogeneity in different cell types with a Mr of 97,000 on fibroblasts, 114,000 on the myelomonocytic cell line U937, and 90,000 on the B lymphoblastoid cell JY. ICAM-1 biosynthesis involves a Mr approximately 73,000 intracellular precursor. The non-N-glycosylated form resulting from tunicamycin treatment has a Mr of 55,000. ICAM-1 isolated from phorbol myristic acetate (PMA) stimulated U937 and from fibroblasts yields an identical major product of Mr = 60,000 after chemical deglycosylation. ICAM-1 MAb interferes with the adhesion of phytohemagglutinin blasts, and the adhesion of the cell line SKW3 to human dermal fibroblast cell layers. Pretreatment of fibroblasts but not lymphocytes with ICAM-1 MAb, and of lymphocytes but not fibroblasts with lymphocyte function-associated antigen 1 MAb inhibits adhesion. Intercellular adhesion is increased by prior exposure of fibroblasts to IL 1, and correlates with induction of ICAM-1.     

Soluble intercellular adhesion molecule-1 (sICAM-1): an overview

Soluble intercellular adhesion molecule-1 (sICAM-1) represents a circulating form of ICAM-1 that is constitutively expressed or is inducible on the cell surface of different cell lines. It serves as a counter-receptor for the lymphocyte function-associated antigen (LFA-1). Interaction between ICAM-1, present on endothelial cells, and LFA-1 facilitates leukocyte adhesion and migration across the endothelium. ICAM-1 and its circulating form have been implicated in the development of any number of diseases.     

Involvement of Rac GTPase activation in phosphatidylcholine hydroperoxide-induced THP-1 cell adhesion to ICAM-1

Increasing evidence indicates that phospholipid oxidation plays important roles in atherosclerosis. Here, we investigated the involvement of Rho-family GTPases inphosphatidylcholine hydroperoxide (PCOOH)-induced THP-1 cell adhesion to ICAM-1. Isoprenoid depletion by fluvastatin and geranylgeranyltransferase inhibition by GGTI-286 suppressed PCOOH-induced cell adhesion to ICAM-1 and F-actin-rich membrane protrusion formation. Pull-down assays demonstrated the activation of Rac1 and Rac2 in PCOOH-treated cells. Pan-Rho-family GTPase inhibitor Clostridium difficile toxin B, Rac-specific inhibitor NSC23776, and RNA interference of the Rac isoforms suppressed the cell adhesion. These findings indicate the involvement of Rac GTPase activation in PCOOH-induced cell adhesion to ICAM-1 via actin reorganization.     

Isolation of the murine intercellular adhesion molecule 1 (ICAM-1) gene. ICAM-1 enhances antigen-specific T cell activation

Cell adhesion molecules in the immune system are believed to play an important role in lymphocyte-target cell conjugate formation. One such molecule, intercellular adhesion molecule 1 (ICAM-1), is important in the function, aggregation, and adherence of leukocytes. Here, we report the isolation and characterization of the murine ICAM-1 gene. We report that the murine ICAM-1 gene is a member of the Ig gene superfamily, has limited homology to its human counterpart, and is expressed in cells of lymphocytic and myeloid lineages. Transfection of the ICAM-1 cDNA into MHC class II-transfected fibroblasts leads to enhancement of the Ag-specific T cell response when the transfectants are used as APC.     

Analysis of the roles of ICAM-1 in neutrophil transmigration using a reconstituted mammalian cell expression model: implication of ICAM-1 cytoplasmic domain and Rho-dependent signaling pathway

Interaction between ICAM-1 (CD54) and fibrinogen (fg) has been shown to enhance leukocyte adhesion, but its specific role in the process of migration across endothelial cell junctions remains unclear. To overcome the problem of multiple adhesion receptors found on endothelial cells, we have engineered stable Chinese hamster ovary cell lines expressing ICAM-1 (Chinese hamster ovary ICAM-1). The transfection of ICAM-1 alone in these cells is sufficient to recapitulate the entire process of neutrophil adhesion and transmigration. This phenomenon was mediated by fg-ICAM-1 interactions, as depletion of fg, as well as the use of an Ab that specifically inhibits ICAM-1-fg interaction (2D5), completely abolished the effect of ICAM-1 expression on PMN transmigration. In addition, this ICAM-1-mediated transmigration is clearly dependent on the occurrence of fg-ICAM-1 interactions on the monolayer, and not on neutrophils, as the preincubation of the PMN with the mAb was ineffective. Furthermore, PMN transmigration, but not adhesion, is totally abolished when the ICAM-1 cytoplasmic domain is deleted, indicating that signaling inside the cell is required to mediate the fg-ICAM-1 effect on transmigration. Using a specific inhibitor of the small GTP-binding protein Rho, we have obtained evidence that this signaling cascade is involved. Thus, our results clearly show that ICAM-1 plays a key role in the migration of leukocytes across cell junctions, and indicate that this phenomenon is not a direct consequence of the enhanced adhesion mediated by the expression of ICAM-1.